About Serine/threonine-protein phosphatase 6 catalytic subunit
Serine/threonine-protein phosphatase 6 catalytic subunit (PPP6C) is a protein
from Homo sapiens identified by UniProt accession
O00743, 305 residues long.
MolForge cross-references it against 0 known binders and
166 disease associations.
Target properties
| Protein name | Serine/threonine-protein phosphatase 6 catalytic subunit |
|---|
| UniProt accession | O00743 |
|---|
| Gene | PPP6C |
|---|
| Organism | Homo sapiens |
|---|
| Length | 305 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (166)
Diseases linked to this target (Open Targets).
- melanoma · score 0.62
- neurodegenerative disease · score 0.53
- cutaneous melanoma · score 0.43
- skin basal cell carcinoma · score 0.37
- bile duct carcinoma · score 0.37
- carcinoma of liver and intrahepatic biliary tract · score 0.37
- superficial spreading melanoma · score 0.37
- squamous cell lung carcinoma · score 0.34
- acute myeloid leukemia · score 0.29
- basal cell carcinoma · score 0.28
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O00743-F1 | alphafold | PREDICTED | 95.86 | — |
Amino-acid sequence (305 residues)
MAPLDLDKYV EIARLCKYLP ENDLKRLCDY VCDLLLEESN VQPVSTPVTV CGDIHGQFYD LCELFRTGGQ VPDTNYIFMG DFVDRGYYSL ETFTYLLALK AKWPDRITLL RGNHESRQIT QVYGFYDECQ TKYGNANAWR YCTKVFDMLT VAALIDEQIL CVHGGLSPDI KTLDQIRTIE RNQEIPHKGA FCDLVWSDPE DVDTWAISPR GAGWLFGAKV TNEFVHINNL KLICRAHQLV HEGYKFMFDE KLVTVWSAPN YCYRCGNIAS IMVFKDVNTR EPKLFRAVPD SERVIPPRTT TPYFL
Explore Serine/threonine-protein phosphatase 6 catalytic subunit with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets